# Copper Peptide Hair Research on GHK-Cu | GHK-Cu Medicine > Copper peptide hair research on GHK-Cu: the 45-patient ALAVAX hair-count RCT, VEGF and Wnt/beta-catenin follicle signaling, and why the effect is non-androgenic, all cited. The follicle file on GHK-Cu, benchmarked: the controlled hair-count signal, the angiogenic mechanism, and the non-androgenic route — with the combination-formula caveat named. ## Copper peptide hair research and the controlled signal Copper peptide hair research has one controlled human anchor, and it is worth stating precisely. In a 6-month trial of 45 men with androgenetic alopecia (Norwood-Hamilton II-V), a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide (ALAVAX) increased hair count by 52.6 at 100 mg/mL and 71.5 at 50 mg/mL, versus 9.6 for placebo (p<0.05), with no adverse events in any group [4]. The caveat is the formula. That trial tested a 5-ALA + GHK combination, not pure GHK-Cu, so the hair-count gain cannot be attributed to GHK alone [4]. It remains the strongest controlled efficacy signal for any GHK-containing topical, which is why it anchors this page — but it is reported here as a combination result, not a clean single-agent finding. This site reports the study as conducted; it does not extrapolate. ## The follicle mechanism: angiogenesis, not androgens Mechanistically, copper peptides act on the follicle through growth-factor and matrix signaling rather than hormones. GHK-Cu raises VEGF and FGF-2 and supports the angiogenesis that feeds an active follicle, and the broader tissue-remodeling profile recruits repair cells and rebuilds the perifollicular matrix [6]. The hair-relevant pathways reported in the research are Wnt/beta-catenin activation, which drives follicles into the active anagen phase, alongside VEGF and HGF support of the dermal papilla [6]. The non-androgenic point matters for how the evidence is read: the follicle effect documented in research does not run through DHT inhibition. The copper-peptide route is matrix-and-angiogenesis-driven, which is mechanistically distinct from androgen-pathway approaches and is why this literature describes a different kind of intervention rather than a hormone blocker [6]. ## What the hair evidence does and doesn't cover Outside the ALAVAX combination trial, the hair-specific evidence is largely preclinical or uses copper-tripeptide analogs, so the controlled human base is thin [4][6]. The supporting rationale is consistent — VEGF upregulation, follicular angiogenesis, anti-apoptotic effects on dermal papilla cells — but it is mechanistic support, not repeated controlled efficacy [6]. That is the honest state of the file: one positive controlled trial of a combination formula, plus a coherent angiogenic mechanism, against a shortage of pure-GHK-Cu hair RCTs. The numbers reported here — the +71.5 versus +9.6 hair-count delta in particular — come from that single combination study and should be read with the formula caveat attached every time [4]. ## What the follicle cells are doing in the research The cellular target for hair effects is the dermal papilla, the cluster of cells at the base of the follicle that governs cycling. In research models GHK-Cu promotes dermal papilla cell proliferation and inhibits their apoptosis, which is the kind of signal that keeps a follicle in its active growth phase rather than letting it regress [6]. The same tissue-remodeling profile that rebuilds skin matrix — collagen, elastin, VEGF, FGF-2 and recruited repair cells — is what supplies and remodels the perifollicular environment [6]. The anagen point is worth stating in mechanism terms. The active growth phase of the hair cycle is anagen, and copper-peptide research reports extended anagen and faster re-entry from the resting telogen phase, driven through Wnt/beta-catenin activation [6]. Because that route runs through growth-factor and matrix signaling rather than hormone metabolism, the literature positions copper peptides as a different category of follicle intervention — angiogenic and matrix-driven — separate from androgen-pathway approaches. The evidence for it remains mostly preclinical, and this page reports it as mechanism, not as a promised outcome. ## Do copper peptides stimulate hair growth? In a 6-month trial of 45 men with androgenetic alopecia, a 5-ALA + GHK complex (ALAVAX) increased hair count by 52.6 (100 mg/mL) and 71.5 (50 mg/mL) versus 9.6 for placebo, with no adverse events [4]. GHK-Cu also raises VEGF and supports follicular angiogenesis in research [6]. ## Does copper peptide regrow hair? The strongest controlled signal is the 45-patient ALAVAX hair-count RCT, which showed significant gains versus placebo over 6 months [4]. Note this tested a 5-ALA + GHK combination, not pure GHK-Cu; mechanistically GHK-Cu increases VEGF and promotes follicular matrix turnover [6]. ## Does copper peptide work for hair growth? Research evidence is supportive but limited: one controlled human trial of a GHK combination showed hair-count gains [4], and copper peptides raise VEGF and stimulate follicular angiogenesis [6]. Most other hair data are preclinical or use copper-tripeptide analogs, so the controlled human base is narrow. ## How long does GHK-Cu take to regrow hair? Controlled hair-count gains in the 5-ALA + GHK trial were measured over a 6-month course [4]. Timelines in the research literature are study-specific and not a clinical recommendation; this site reports findings only and does not state a personal regrowth schedule. ## Is copper a DHT blocker? No. Copper-peptide hair effects in research are non-androgenic: the documented follicle route runs through Wnt/beta-catenin and VEGF/HGF signaling and perifollicular matrix remodeling rather than DHT inhibition [6]. The mechanism described in the literature drives follicles toward anagen by angiogenic and matrix pathways, not by blocking androgens. --- A benchmark sheet for the GHK-Cu copper-tripeptide literature — every study clocked, every number cited, and no clinic behind the console.